logo

For the Inventor, By the Inventor

Frontenac, MO, United States of America

Zhude Tu

USPTO Granted Patents = 15 

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 35(Granted Patents)


Location History:

  • Eureka, MO (US) (2008 - 2012)
  • Frontenac, MO (US) (2009 - 2024)
  • St. Louis, MO (US) (2019 - 2024)

Company Filing History:

goldMedal15 out of 1,586 
 
Washington University
 patents
silverMedal1 out of 15,488 
 
University of California
 patents
where one patent can have more than one assignee

Years Active: 2008-2024

Loading Chart...
15 patents (USPTO):Explore Patents
1. 12037329 - SphK inhibitors and methods of making and using same (2024-07-16),
2. 12012394 - Alpha-synuclein ligands (2024-06-18),
3. 10676467 - Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof (2020-06-09),
4. 10421722 - Sulfur-containing compounds targeting vesicular acetylcholine transporter (2019-09-24),
5. 10300155 - Alpha-synuclein ligands (2019-05-28),
6. 8658131 - Compounds comprising 4-benzoylpiperidine as a sigma-1-selective ligand (2014-02-25),
7. 8506927 - Pegylated fluorobenzamide analogues, their synthesis and use in diagnostic imaging (2013-08-13),
8. 8193360 - Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging (2012-06-05),
9. 8168650 - Therapeutic uses of bicyclic ligands of sigma 2 receptor (2012-05-01),
10. 7947838 - Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging (2011-05-24),
11. 7893266 - Detection of cancer cells in vitro using sigma-2 receptor ligands as radiotracers (2011-02-22),
12. 7659400 - Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging (2010-02-09),
13. 7612206 - Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors (2009-11-03),
14. 7612085 - Sigma 2 receptor ligands and therapeutic uses therefor (2009-11-03),
15. 7390902 - Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors (2008-06-24),

Title: Zhude Tu: Innovator in SphK Inhibitors and Alpha-Synuclein Ligands

Introduction

Zhude Tu is a prominent inventor based in Frontenac, MO (US), known for his significant contributions to the field of biochemistry and pharmacology. He holds a total of 15 patents, showcasing his innovative approach to developing therapeutic agents.

Latest Patents

Among his latest patents is the development of SphK inhibitors and methods of making and using them. This patent provides for an SphK2 inhibiting agent, specifically a 1,2,3-triazole that exhibits SphK2 inhibiting activity and selectivity. Another notable patent involves alpha-synuclein ligands, which are compounds useful for detecting synucleinopathies, including Parkinson's disease (PD). These inventions highlight his focus on addressing critical health challenges through innovative solutions.

Career Highlights

Zhude Tu has had a distinguished career, working at esteemed institutions such as Washington University and the University of California. His research has significantly advanced the understanding of various biochemical pathways and their implications in disease.

Collaborations

Throughout his career, Tu has collaborated with notable colleagues, including Robert H. Mach and Michael John Welch. These partnerships have contributed to the success of his research and the development of his patented inventions.

Conclusion

Zhude Tu's work in developing SphK inhibitors and alpha-synuclein ligands demonstrates his commitment to innovation in the medical field. His contributions continue to pave the way for advancements in therapeutic strategies for complex diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…